These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 16686722

  • 21. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR, Toglia MR, Forero-Schwanhaeuser S, He W.
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [Abstract] [Full Text] [Related]

  • 22. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 23. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
    Kaplan SA, Goldfischer ER, Steers WD, Gittelman M, Andoh M, Forero-Schwanhaeuser S.
    Aging Male; 2010 Jun; 13(2):100-7. PubMed ID: 20001469
    [Abstract] [Full Text] [Related]

  • 24. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
    Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.
    J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Solifenacin at 3 years: a review of efficacy and safety.
    Pelman RS, Capo JP, Forero-Schwanhaeuser S.
    Postgrad Med; 2008 Jul; 120(2):85-91. PubMed ID: 18654073
    [Abstract] [Full Text] [Related]

  • 27. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
    Kelleher C, Cardozo L, Kobashi K, Lucente V.
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Jun; 17(4):382-8. PubMed ID: 16283422
    [Abstract] [Full Text] [Related]

  • 30. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
    Slavov Ch, Popov E, Slavov S, Dimitrov R, Doganov N, Chernev T.
    Akush Ginekol (Sofiia); 2010 Jun; 49(3):16-21. PubMed ID: 20734651
    [Abstract] [Full Text] [Related]

  • 31. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Relationships between symptoms, symptom bother, and health-related quality of life in patients with overactive bladder taking solifenacin or placebo in the VIBRANT study.
    Crosby RD, Mathias SD, Marshall TS.
    Int J Clin Pract; 2011 Feb; 65(2):211-8. PubMed ID: 21235700
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prospective open label study of solifenacin for overactive bladder in children.
    Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M.
    J Urol; 2010 Oct; 184(4 Suppl):1668-73. PubMed ID: 20728124
    [Abstract] [Full Text] [Related]

  • 39. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
    Choo MS, Doo CK, Lee KS.
    Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.